Concerns about gastrointestinal tolerability continue to weigh on Lilly’s tirzepatide, despite improvements seen in a Phase II dose-escalation study. Lilly believes the adverse events are manageable.
Eli Lilly & Co. investors have been eagerly awaiting more details on the investigational dual GIP and GLP-1 receptor agonist tirzepatide for type 2 diabetes, but while new Phase II data presented at the American Diabetes Association Scientific Sessions, showed an improvement, it did not alleviate concerns about tolerability.
Lilly announced incremental data from four separate studies of tirzepatide, which showed improvements in markers of beta-cell function and insulin...
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Oral RNA splicing modulator has gone into a Phase II/III trial
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
